Evidence map›Paper›PMID 31768351›Full record

ArticleGastrointestinal tumors2019

Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort.

Andrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, Eleonora Molinaro, Vincenzo Dadduzio, Mario Domenico Rizzato, Antonio Pellino, Luca Faloppi, Giorgia Marisi, Paola Ulivi and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastrointestinal tumors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Andrea Casadei-GardiniDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Leonardo SolainiDepartment of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Laura RiggiDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Eleonora MolinaroDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Vincenzo DadduzioUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Mario Domenico RizzatoUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Antonio PellinoUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Luca FaloppiMedical Oncology, University Hospital of Cagliari, Cagliari, Italy.
Giorgia MarisiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Paola UliviBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Matteo CanaleBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Giulia OrsiDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Giulia RovestiDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Kalliopi AndrikouDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Andrea SpallanzaniDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Fabio GelsominoDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Francesco Giuseppe FoschiDepartment of Internal Medicine, Degli Infermi Hospital, Faenza, Italy.
Fabio ContiDepartment of Internal Medicine, Degli Infermi Hospital, Faenza, Italy.
Alessandro CucchettiDepartment of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Giorgio ErcolaniDepartment of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Paola BiasonUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Sara LonardiUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Stefano CascinuDepartment of Oncology and Hematology, Division of Oncology, University Hospital Modena, Modena, Italy.
Mario ScartozziUnit of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThe aim of the present study is to evaluate a new index influenced by the balance between the immune system, α-fetoprotein (AFP), and lactate dehydrogenase (LDH) (RAPID index) as a prognostic factor in patients treated with sorafenib.

methodsThis study was conducted on a training cohort of 159 hepatocellular carcinoma (HCC) patients and a validation cohort of 68 HCC patients treated with sorafenib. The RAPID index was calculated as neutrophil/lymphocyte count × LDH × AFP.

resultsIn the training cohort, the median overall survival (OS) was 23.2 months (95% CI 11-25) and 12.1 months (95% CI 9-15) for patients with a low (≤3,226) and high (>3,226) RAPID index, respectively (ref. <3,226, HR = 0.56, 95% CI 0.35-0.88,

conclusionThe low cost, easy assessment, and reproducibility of a full blood count make the RAPID index a promising tool for assessing HCC prognosis in future clinical practice.

Indexed as

Lactate dehydrogenaseNeutrophil-to-lymphocyte ratioPlatelet-to-lymphocyte ratioSystemic inflammatory indexα-Fetoprotein

Identifiers

PMID31768351
PMCPMC6873000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.